Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Поддерживающая терапия обинутузумабом при лечении пациентов с лимфомой центральной нервной системы, у которых достигнут полный или частичный ответ

22 сентября 2026 г. обновлено: Providence Health & Services

Поддерживающая терапия обинутузумабом при первичной лимфоме центральной нервной системы у пациентов с полным или частичным ответом

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Обзор исследования

Подробное описание

PRIMARY OBJECTIVE:

I. To determine the effect of maintenance obinutuzumab on duration of response (partial response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain PR or CR to first-line treatment with high-dose methotrexate-based chemotherapy.

SECONDARY OBJECTIVES:

I. To evaluate overall survival after PR or CR (overall survival [OS]-PRCR). II. To evaluate neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.

III. Progression-free survival (PFS) and overall survival (OS) will be calculated.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.

ARM II (OBSERVATION): Patients undergo observation for a total of 2 years.

Тип исследования

Интервенционный

Регистрация (Оцененный)

28

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Учебное резервное копирование контактов

Места учебы

    • New York
      • New York, New York, Соединенные Штаты, 10065
        • Рекрутинг
        • Memorial Sloan Kettering Cancer Center
        • Контакт:
          • Lindey Myers
          • Номер телефона: 917-453-2968
          • Электронная почта: myersl1@mskcc.org
        • Главный следователь:
          • Christian Grommes, MD
    • Ohio
      • Cleveland, Ohio, Соединенные Штаты, 44195
        • Отозван
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Соединенные Штаты, 97225
        • Рекрутинг
        • Providence Health & Services; Providence Neurological Specialties
        • Главный следователь:
          • Prakash Ambady, MD
        • Контакт:
        • Контакт:
    • Pennsylvania
      • Hershey, Pennsylvania, Соединенные Штаты, 17033
        • Рекрутинг
        • Pennsylvania State University
        • Главный следователь:
          • Dawit Aregawi, MD
        • Контакт:
        • Контакт:
    • Vermont
      • Burlington, Vermont, Соединенные Штаты, 05405
        • Рекрутинг
        • University of Vermont
        • Контакт:
        • Контакт:
        • Главный следователь:
          • Alissa Thomas, MD
    • Virginia
      • Charlottesville, Virginia, Соединенные Штаты, 22903
        • Рекрутинг
        • University of Virginia
        • Главный следователь:
          • David Schiff, MD
        • Контакт:
          • Nija Desai
          • Номер телефона: 434-982-6455
          • Электронная почта: NND2A@uvahealth.org
        • Контакт:
          • Patrick Heffernan
          • Номер телефона: 434-243-9508
          • Электронная почта: YWW2NJ@uvahealth.org
    • Washington
      • Seattle, Washington, Соединенные Штаты, 98122
        • Рекрутинг
        • Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute
        • Контакт:
        • Контакт:
          • Gary Brown
          • Номер телефона: 206-320-2608
          • Электронная почта: gary.brown@swedish.org
        • Главный следователь:
          • Alipi Bomn, MD

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid (CSF); diagnosis must be documented by pathology report.
  • Must have undergone first-line treatment with a high-dose methotrexate-based chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is defined as >= 3 grams/m^2; methotrexate dose reduction for creatinine clearance < 100 ml/min is permitted
  • Must be within 75 days of completion of first-line treatment regimen at the time of randomization; must have achieved objective response (PR or CR/unconfirmed complete response [CRu]) to first-line treatment
  • Brain magnetic resonance imaging (MRI) documenting objective response must be obtained within 30 days before randomization
  • If CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or a slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; for CRu, some patients will have a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often difficult to ascertain whether this represents a residual nidus of tumor or scar tissue; if the abnormality does not change or slowly involutes without therapy and corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeks
  • Karnofsky performance status (KPS) >= 60; Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
  • Signed informed consent form (ICF)
  • Ability and willingness to comply with the requirements of the study protocol
  • Total bilirubin < 3 x the upper limit of normal (ULN), ≤ 7 days before date of randomization
  • Creatinine clearance > 30 mL/min (calculated according to institutional standards or using Cockcroft-Gault formula), ≤ 7 days before date of randomization
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 x ULN, ≤7 days before date of randomization
  • Platelet ≤ 75,000 cells/mm^3, ≤ 7 days before date of randomization
  • Hemoglobin > 9 g/dL, ≤ 7 days before date of randomization
  • Absolute neutrophil count > 1.5 x 10^3 cells/mm^3, ≤ 7 days before date of randomization
  • Surgically sterile or agree to use effective contraception using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly while receiving obinutuzumab and >= 18 months after the last dose of obinutuzumab for women, and 180 days after the last dose of obinutuzumab for men

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma
  • Known hypersensitivity to any of the study drugs
  • History of other malignancy that could affect compliance with the protocol or interpretation of results
  • Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible; patients with a malignancy that has been treated, but not with curative intent, will also be excluded, unless the malignancy has been in remission without treatment for >= 2 years prior to randomization
  • Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study randomization
  • Major surgery within 4 weeks prior to study randomization
  • Known infection with human immunodeficiency virus (HIV)
  • Positive hepatitis serologies:
  • Hepatitis B (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management
  • Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion in the study on a case-by-case basis
  • Women who are pregnant or lactating
  • Vaccination with a live vaccine a minimum of 4 weeks prior to study randomization

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Одинокий

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Arm I (obinutuzumab

Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.

Given IV

Другие имена:
  • Газива
  • РО5072759
  • GA101
  • Моноклональное антитело к CD20 R7159
  • ГА-101
  • R7159
  • РО 5072759
  • РО-5072759
  • хуМАБ (CD20)

Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.

Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.

Активный компаратор: Arm II (observation)

Patients undergo observation for a total of 2 years.

Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.

Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Partial response (PR) or complete response (CR) duration
Временное ограничение: From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years

PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios.

From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall survival (OS) after CR
Временное ограничение: From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years

OS after PR or CR will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios.

From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
Neurocognitive function - Wechsler Adult Intelligence Scale
Временное ограничение: Up to 2 years

Will be measured by the Wechsler Adult Intelligence Scale. Scale range 0 to 16 Forward; 0 to 14 Backward. Higher the score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20-item
Временное ограничение: Up to 2 years

Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module-20 (EORTC QLQ-BN20) questionnaire. Scale 20 to 80 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Progression free survival (PFS)
Временное ограничение: From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years

PFS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
Overall survival
Временное ограничение: From the start date of first-line PCNSL treatment to death, assessed up to 2 years.

OS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
Neurocognitive function - Hopkins Verbal Learning Test-Revised
Временное ограничение: Up to 2 years

Will be measured by the Hopkins Verbal Learning Test-Revised. Test evaluates total recall, delayed recall, percent of retention, and recognition. Higher score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Neurocognitive function - Grooved Pegboard Test
Временное ограничение: Up to 2 years

Will be measured by the Grooved Pegboard Test. Scale 0 seconds to time of completion in minutes and seconds. Higher time to completion means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Neurocognitive function - Trail Making Test
Временное ограничение: Up to 2 years

Will be measured by the Trail Making Test. Scale Part A: 0 seconds to 100 seconds (time of greater than 100 seconds discontinues the test. Scale Part B: 0 seconds to 300 seconds (time of greater than 300 seconds discontinues the test. Number of errors recorded. Higher time to completion and greater number of errors means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Neurocognitive function - Brief Test of Attention
Временное ограничение: Up to 2 years

Will be measured by the Trail Making Test. Scale 0 to 20 points. Higher score mean better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item
Временное ограничение: Up to 2 years

Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Core 30-item (EORTC QLQ-C30) questionnaire. Scale 30 to 126 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test.

Up to 2 years

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Главный следователь: Prakash Ambady, MD, Providence Health & Services

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

13 марта 2024 г.

Первичное завершение (Оцененный)

15 сентября 2028 г.

Завершение исследования (Оцененный)

15 сентября 2029 г.

Даты регистрации исследования

Первый отправленный

28 июня 2023 г.

Впервые представлено, что соответствует критериям контроля качества

8 декабря 2023 г.

Первый опубликованный (Действительный)

18 декабря 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

23 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

22 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • PHS-OB-PCNSL-01
  • ML29496 (Другой идентификатор: Genentech, Inc.)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться